Rocket Price To Sales Ratio from 2010 to 2024
| RCKT Stock | USD 14.39 0.19 1.34% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check Rocket Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rocket Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.5 M, Interest Expense of 3.3 M or Selling General Administrative of 77 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.37. Rocket financial statements analysis is a perfect complement when working with Rocket Pharmaceuticals Valuation or Volatility modules.
Rocket | Price To Sales Ratio |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.